Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Down 6.6% – Here’s Why

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) dropped 6.6% during trading on Tuesday . The stock traded as low as $10.80 and last traded at $10.80. Approximately 711 shares traded hands during mid-day trading, a decline of 94% from the average daily volume of 11,747 shares. The stock had previously closed at $11.56.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

Santen Pharmaceutical Stock Performance

The company’s fifty day moving average price is $11.03 and its 200 day moving average price is $10.66. The firm has a market capitalization of $3.35 billion and a price-to-earnings ratio of 0.10.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan?based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over?the?counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post?operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.